This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:

AstraZeneca & Daiichi Sankyo Report the P-III (TROPION-Lung01) Study Results of Datopotamab Deruxtecan (Dato-DXd) to Treat Advanced Non-Squamous NSCLC

Read More: AstraZeneca & Daiichi Sankyo                                                        

Novartis Highlights Results from the P-III (ALIGN) Study of Atrasentan for the Treatment of IgA Nephropathy (IgAN) at ERA 2024

Read More: Novartis                                                                                              

CG Oncology to Highlight the P-II (CORE-001) Trial Data of Cretostimogene Grenadenorepvec Plus Keytruda for Bladder Cancer at ASCO 2024

Read More: CG Oncology                                                                                        

Neuren Pharmaceuticals Reports the P-II Study Results of NNZ-2591 for Pitt Hopkins Syndrome

Read More: Neuren Pharmaceuticals                                                              

Innovent Reports the P-III (CLEAR-1) Study Data of Picankibart for Treating Plaque Psoriasis in Chinese Patients

Read More: Innovent                                                                                           

Merck Reports the Data from P-III (KEYNOTE-522) Study of Keytruda for Treating Triple Negative Breast Cancer (TNBC)

Read More: Merck                                                                                              

Johnson & Johnson Reports P-III (MDD3001) Study Data of Seltorexant for Treating Major Depressive Disorder

Read More: Johnson & Johnson                                                                         

Novartis Highlights the P-III (REMIX) Trial Data of Remibrutinib to Treat Chronic Spontaneous Urticaria at EAACI 2024

Read More: Novartis                                                                                                

Sanofi Reports the US FDA’s sBLA Acceptance of Sarclisa to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Read More: Sanofi                                                                                                      

The US FDA Accepts and Grants Priority Review to Roche’s NDA of Inavolisib for Treating Breast Cancer

Read More: Roche                                                                                        

BMS’ Opdivo Plus Cisplatin and Gemcitabine Gain EC’s Approval for Treating Urothelial Carcinoma

Read More: BMS                                                                                                        

Tris Pharma’s Onyda XR Gains the US FDA’s Approval for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Read More: Tris Pharma                                                                                           

InxMed Reveals Data from the P-Ib/II Study of Ifebemtinib Plus Garsorasib for Non-Small Cell Lung Cancer (NSCLC)

Read More: InxMed                                                                                              

BMS Reports the US FDA’s Approval of Breyanzi for Treating Mantle Cell Lymphoma

Read More: BMS                                                                                                         

Sanofi & Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Chronic Obstructive Pulmonary Disease (COPD)

Read More: Sanofi & Regeneron                                                                       

AbbVie Reports the CHMP’s Positive Opinion of Skyrizi (Risankizumab) to Treat Ulcerative Colitis

Read More: AbbVie                                                                                                

Eli Lilly Receives the US FDA’s Approval for Retevmo (Selpercatinib) to Treat Thyroid Cancer or Solid Tumors

Read More: Eli Lilly                                                                                                   

The EC Grants Approval to Celltrion’s Omlyclo (Biosimilar, Xolair)

Read More: Celltrion                                                                                                  

Fresenius Reports the US FDA’s BLA Acceptance of FKS518 (Biosimilar, Denosumab)

Read More: Fresenius                                                                                       

Bio-Thera Collaborates with STADA for the Commercialization of BAT2506 (Biosimilar, Simponi)

Read More: Bio-Thera & STADA                                                                        

Merck Animal Health’s Innovax-ND-H5 Vaccine Gains the EC’s Marketing Authorization for Chickens

Read More: Merck Animal Health                                                                            

Elanco Reports the US FDA’s Review Completion of Bovaer to be Used Across the US Dairy Industry

Read More: Elanco                                                                                         

Oncocross and JW Pharmaceutical Expand their Partnership to Develop New Therapies Using AI in Anticancer and Regenerative Medicine

Read More: Oncocross & JW Pharmaceutical                                                   

GlycoNex and PrecisemAb Join Hands to Develop New Anti-Glycan Antibodies for Cancer Therapy

Read More: GlycoNex & PrecisemAb                                                                 

Terumo Cardiovascular Reports the US FDA’s Approval of CDI OneView Monitoring System

Read More: Terumo Cardiovascular                                                                    

The US FDA Grants Clearance to InnoVoyce’s Vylo 455nm Blue Light Laser System

Read More: InnoVoyce

Johnson & Johnson to Acquire Numab's Yellow Jersey Therapeutics for an Aggregate of ~$1.25B

Read More: Johnson & Johnson & Numab                                                         

Asahi Kasei Reports the Acquisition of Calliditas Therapeutics for an Aggregate of ~$1.11B

Read More: Asahi Kasei & Calliditas Therapeutics                                               

Merck Expands its Ophthalmologic Portfolio Through the Acquisition of EyeBio

Read More: Merck & EyeBio                                                                                

Atara Biotherapeutics Reports Preclinical Data on ATA3219 to Treat B-Cell Driven Autoimmune Diseases

Read More: Atara Biotherapeutics                                                                      

Related Post: PharmaShots Weekly Snapshots (May 20 – May 24, 2024)